Interim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021 Introduction of pipeline program IMR-261, a novel oral clinic-ready Nrf2 activator shown to reactivate fetal hemoglobin and reduce VOCs in preclinical models of sickle cell disease Building […]
Other News
Nuwellis, Inc. Announces Third Quarter 2021 Financial Results
MINNEAPOLIS, Nov. 09, 2021 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the third quarter ended September 30, 2021, which included the following highlights: Generated $1.9 million in total revenue, representing a decline of 3% compared to the prior-year period Generated $6.3 million in total revenue […]
Verve Therapeutics Reports Preclinical Data Demonstrating Potent Editing of ANGPTL3 Gene Using Proprietary GalNAc-LNP Delivery Technology in Non-Human Primates
ANGPTL3 Base Editor Delivered via Internally Developed GalNAc-LNPs Potently Reduced Blood ANGPTL3 Protein by 94-97% in a Novel NHP Model of Homozygous Familial Hypercholesterolemia GalNAc-LNP Delivery of ANGPTL3 Base Editor Led to Potent Editing in both LDLR-Deficient and Normal NHP Livers, Supporting Potential Broad Applicability CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE […]
InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-CGuard™ sales generated 24% YoY revenue growth- -CGuard™ EPS received a positive opinion from the French National Authority for Health (HAS) regarding reimbursement in France- – $37.1 million in cash, cash equivalents and short-term bank deposits as of September 30, 2021, provides runway into first half of 2023- -Management to […]
Acarix accelerates US market entry with Proximo Medical as commercialization partner
Press release (MAR) Malmö, Sweden, November 9, 2021 Acarix accelerates US market entry with Proximo Medical as commercialization partner Acarix today announced the signing of a Commercial Access agreement with Proximo Medical, LLC, to rapidly initiate the commercialization of the CADScor system in the US market. With the agreement, Acarix immediately gains […]
Atrion Reports Third Quarter Results
ALLEN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) — Atrion Corporation (NASDAQ: ATRI) today announced its results for the third quarter ended September 30, 2021. Revenues totaled $42.9 million compared to $33.8 million for the same period in 2020. Net income for the third quarter of 2021 totaled $8.3 million, an […]
Cardiovascular Systems, Inc. Reports Fiscal 2022 First Quarter Financial Results
Conference Call Scheduled for Today, November 9, 2021, at 8:00 AM CT (9:00 AM ET) Revenues of $58.4 million decreased 3.6% compared to first quarter last year Procedure volumes adversely impacted by hospital constraints and staffing shortages caused by the COVID-19 Delta variant Management provides updated fiscal year 2022 revenue […]
Cleerly Expands Board of Directors with Three New Members
NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, announced today it has expanded its board of directors with three new medical and investment leaders. Kevin M. King, Glenn D. Steele Jr., MD, PhD and Roy Beveridge MD have joined the board to advise the […]
OmniLife and ACTION Network Solidify Collaboration to Drive Innovation
LEXINGTON, Ky.–(BUSINESS WIRE)–OmniLife, a health technology communication and collaboration platform, has finalized its formal collaboration with the Advanced Cardiac Therapies Improving Outcomes Network, or ACTION. The organizations will work together to drive innovation around patient care and clinical decision making, specifically with the goal of improving outcomes for children with […]
Edwards Announces Six-month Data From Transcatheter Tricuspid Replacement Program
IRVINE, Calif., Nov. 6, 2021 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) announced that results from a clinical trial of the company’s EVOQUE transcatheter tricuspid valve replacement system demonstrated that favorable patient outcomes were sustained at six months. Results from the TRISCEND study, treating patients with tricuspid regurgitation, were presented during the late-breaking clinical […]



